Background: Single preoperative gabapentinoid (gabapentin and pregabalin) administration has been associated with respiratory depression during Phase I anaesthesia recovery. In this study, we assess for associations between chronic (home) use and perioperative administration (preoperative and postoperative) of gabapentinoids, and risk for severe over-sedation or respiratory depression as inferred from the use of naloxone. Methods: From 2011 to 2016, we identified patients undergoing general anaesthesia discharged to standard postoperative wards and administered naloxone within 48 h of surgery in a single centre. These patients were 2:1 matched on age, sex, and type of procedure. Patient and perioperative characteristics were abstracted and compared to assess for risk for naloxone administration. Results: We identified 128 patients that received naloxone after operation [odds ratio 1.2; 95% confidence interval (CI) 1.0, 1.4 per 1000 general anaesthetics]. Patients on chronic or postoperative gabapentinoid therapy were at significantly higher risk for receiving naloxone after operation. Multivariable analysis detected significant interactions between chronic and postoperative use of gabapentinoids, where continuation of chronic gabapentinoid medications into the postoperative period was associated with an increased rate of naloxone administration (6.30, 95% CI 2.4, 16.7; P¼0.001). Obstructive sleep apnoea (P¼0.005) and preoperative disability (P¼0.003) were also associated with an increased risk for postoperative naloxone administration. Patients who received naloxone had longer hospital stays and higher rates of postoperative delirium. Conclusions: Continuation of chronic gabapentinoid medications into the postoperative period is associated with the increased use of naloxone to reverse over-sedation or respiratory depression. Such patients requiring this therapy warrant high levels of postoperative monitoring.
Editor's key points
Gabapentinoids may be useful adjuncts for perioperative analgesia, although factors increasing respiratory risk are unclear. Factors associated with postoperative naloxone administration (as an indicator of respiratory depression) were studied. Continuing chronic gabapentinoids after operation increased the risk of naloxone administration, with longer hospitalisation and increased delirium. Further work is needed to understand the adverse effects of chronically administered, centrally acting adjuncts perioperatively.
A recent letter in the National Patient Safety Foundation newsletter argued that, because there were so many identified risk factors for opioid-related respiratory depression, 'that all patients receiving opioids postoperatively should be monitored for respiratory depression'. 1 While we do not disagree with this assertion, universal monitoring of all patients is not feasible in the current clinical setting. Therefore, we believe it is important to identify risk factors associated with postoperative respiratory depression, in order to focus efforts on the most high-risk individuals. Gabapentin and pregabalin (gabapentinoids) are anticonvulsant medications commonly used to treat neuropathic painful conditions (e.g. postherpetic neuralgia) or fibromyalgia. The off-label use of these medications has been explored as adjuvant analgesics during surgical procedures, and observations from meta-analyses suggest that these medications provide modest reduction in both postoperative pain and opioid analgesic requirements.
2e4 These meta-analyses have not detected that the use of these medications was associated with increased rates of postoperative respiratory depression, 2e4 and support the widely held opinion that these medications are devoid of respiratory depressive properties. 5 Because of these opioid-sparing properties, gabapentinoids are becoming increasingly popular in perioperative multimodal analgesic regimens. Our institution has also introduced gabapentinoids in several enhanced perioperative recovery protocols. 6, 7 Despite these modest antinociceptive effects, there is not a precise assessment of the overall riskebenefit ratio or costebenefit analysis of perioperative gabapentinoid regimens. Specifically, these medications were associated with an increased risk for postoperative sedation, 2e4 and the compounding effects of this sedation with that of concomitantly used opioids and benzodiazepines were rarely quantified. Further, there is an increasing recognition that prospective randomised controlled trials, which are considered the gold standard used to demonstrate the efficacy of a therapy, may be problematic in determining the safety of studied therapies, especially with less common adverse events. 8 In fact, the majority of regulatory actions on drug safety arise from case reports. 9, 10 To that end, we have reported that the administration of gabapentinoids before both elective joint arthroplasty surgery and laparoscopic surgery increased the risk for episodes of respiratory depressive episodes during early (Phase I) anaesthesia recovery. 11, 12 We have also reported that patients who experience episodes of respiratory depression during Phase I recovery have a much higher risk for developing severe episodes of opioid-related adverse effects requiring naloxone administration after dismissal from the postanaesthesia care unit (PACU). 13 However, the association between gabapentinoid therapy and the risk of developing severe opioid-related adverse effects after discharge from the PACU has not been fully investigated. A recent large observational study found an association between opioid-related death among patients on chronic opioid therapy for nonmalignant pain and concomitant gabapentin therapy.
14 Thus, given that opioid analgesics are commonly used in the postoperative period, assessing the risk of perioperative gabapentin therapy after PACU discharge has taken on an increased importance. Our primary aim was to examine whether patterns of gabapentinoid therapies (chronic vs acute use) increase the risk for over-narcotisation in the postoperative period. In a caseecontrol retrospective study design, we examine the association between naloxone administration, as a surrogate marker for serious postoperative over-narcotisation, and gabapentinoid use. As a secondary aim, we assess for other potential associations between clinical factors and the need for postoperative naloxone administration.
Methods
This study was approved by the Mayo Clinic, Rochester MN, USA, Institutional Review Board (Protocol Number 16-006387, approved on August 26, 2016, handled by Resa Jo Jeche). Consistent with Minnesota Statute 144.295, all patients in this study provided prior authorisation for research use of their medical records.
Study design and patient selection
The methods of this study are similar to our earlier study on postoperative naloxone administration (data sets from the previous and current studies do not overlap). 13 This study is representative of a high-volume surgical practice within a major tertiary academic institution. This study used a retrospective caseecontrol design that assessed the patient and procedural characteristics associated with the requirement of postoperative naloxone administration. We retrospectively reviewed the institutional medical records from July 1, 2011 to December 31, 2015, to identify adult patients who (1) underwent general anaesthesia and were extubated in the operating room or the PACU, and (2) were administered with naloxone within 48 h of dismissal from anaesthetic care on a standard postoperative ward (e.g. non-intensive care unit setting). Patients who remained intubated after dismissal from anaesthetic care and transferred to an intensive care unit (ICU) were excluded. Patients were also excluded if naloxone was administered to treat opioid-induced pruritus, as assessed from notes in medical records. For each case, two control patients were matched on age, sex, exact type of surgery, and within 2 yr of the procedure.
Data abstraction
Electronic medical records were abstracted for patient characteristics; comorbid conditions; preoperative, intraoperative, and postoperative variables; postoperative course; and complications using automated data search software, 15 The anaesthetic and surgical records were reviewed for surgical procedure; anaesthetic technique (general anaesthesia with or without neuraxial analgesia); duration of anaesthesia; choice of volatile agent (isoflurane vs other); the use of neuromuscular blocking drugs and reversal (only neostigmine was used during the study time frame); the use of propofol infusion; perioperative use of acetaminophen, nonsteroidal anti-inflammatory drugs (ketorolac or celecoxib), gabapentinoids (preoperative and postoperative), midazolam (preoperative and postoperative), and ketamine; and the dose of systemic opioid analgesics (during the procedure and Phase I recovery). The doses of systemic opioid analgesics were converted to i.v. morphine equivalents using published guidelines. 19, 20 If used, the dose of remifentanil was not considered for calculating i.v. morphine equivalents because of the short half-life of this particular opioid (one patient). For those patients who were admitted to the PACU for Phase I recovery, we reviewed the duration of PACU stay for the occurrence of respiratory-specific events. During Phase I recovery, registered nurses continuously monitored patients for four types of respiratory-specific events: hypoventilation (three episodes of <8 respirations min À1 ), apnoea (episode of apnoea !10 s), hypoxaemia [three episodes of oxyhaemoglobin desaturations as measured by pulse oximetry (<90% with or without nasal cannula)], and 'pain/sedation mismatch' {defined as Richmond AgitationeSedation Score (RASS) 21 ¼e3 to e5 and a numeric pain score >5 [from a scale of 0e10 (worst pain imaginable)]}. 22, 23 Any patient who has a respiratory-specific event must have a subsequent 60 min period free of further events in order to be transferred to a non-monitored inpatient ward. Patients who had repeated events were discharged to an advanced monitored care setting, or were continuously monitored for oxyhaemoglobin desaturation via a pulse oximeter monitored by telemetry. For this study, we also considered the administration of naloxone during Phase I recovery as an episode of respiratory depression. Otherwise, the discharge criteria for Phase I recovery were based on standard criteria. 24 Postoperative opioid, benzodiazepine, and gabapentinoid administrations were recorded from the time of discharge from anaesthetic control to the time of naloxone administration. For control patients, the postoperative administration of these medications from the time of anaesthesia discharge to the time of naloxone administration for the matched case was recorded. Postoperative opioids were then converted to i.v. morphine equivalents, and adjusted for time by dividing by the number of hours between anaesthesia discharge to naloxone administration (or corresponding time for control patients). If naloxone administration was recorded, the primary indication for administration was recorded and categorised as treatment for isolated respiratory depression, over-sedation, or cardiovascular collapse. Other interventions in addition to administration of naloxone were also recorded.
Outcomes and complications
Postoperative records were reviewed for hospital length of stay, ICU admissions, and the need for emergency response team activation. Records were also reviewed for postoperative complications, which included other pulmonary complications (pneumonia), neurological complications (e.g. delirium and cerebrovascular events), myocardial infarction, thromboembolic complications, sepsis or multi-organ failure, or mortality (during hospitalisation and 30-day mortality). Delirium during hospitalisation was detected using the standardised confusion assessment method for the ICU (CAM-ICU). 25 In our practice, CAM-ICU has been applied to all hospitalised surgical patients upon admission and every 12 h thereafter, and the results were reviewed from electronic medical records.
Statistical analyses
Data are summarised using mean (standard deviation) or median (25th and 75th percentiles) for continuous variables and frequency percentages for nominal variables. The incidence of postoperative naloxone administration was calculated using Wald method. Analyses to assess characteristics potentially associated with naloxone use were performed using conditional logistic regression taking into account the 1:2 matched set caseecontrol study design. Patient and procedural variables were assessed for potential association with postoperative naloxone administration with multivariable logistic regression, with the exception of age, sex, and type of procedure, as these were matching variables in the study design. BMI, anaesthesia duration, and opioid dose [both perioperative (intraoperative and Phase I recovery) and postoperative (from end Phase I recovery to the time of naloxone administration)] were modelled as continuous variables, and all other characteristics were modelled as nominal variables. The use of preoperative gabapentin at our institution is largely surgeon or procedure specific as part of multimodal analgesic pathways. Consequently, by matching cases and controls exactly on the type of procedure, we substantially matched caseecontrol sets on the use of preoperative gabapentinoid, which limits our ability to assess this characteristic as a risk factor. Nonetheless, we did include preoperative gabapentinoid as an adjustor variable in our multivariable model. From initial multivariable analyses, significant interactions were detected between chronic/home and postoperative use of gabapentinoids, and similarly with benzodiazepines. For these reasons, four-level categorical variables were created representing combinations of chronic/home use and postoperative administration of these select medication categories. To explore further if there was a dose relationship between chronic use of gabapentinoids and naloxone administration, we performed a post hoc analysis where the combination of chronic use and postoperative administration was further divided into 'low' and 'high' doses of chronic gabapentinoid (see the given definition of dosing level). For patients with chronic use of gabapentinoid prior to surgery who received gabapentinoid postoperatively, the postoperative gabapentinoid was administered according to their home schedule. Thus we made no further adjustments for postoperative dosing in this additional analysis.
Two-tailed P-values are reported and are not adjusted for multiple comparisons. Analyses were performed using SAS statistical software (version 9.2; SAS Institute, Inc., Cary, NC, USA).
Results
During the study time frame, 110 019 patients underwent general anaesthesia and were subsequently admitted to standard postoperative wards. Of these patients, 128 were administered with naloxone within 48 h of surgery under general anaesthesia. This yielded a rate of 1.2 naloxone administrations [95% confidence interval (CI) 1.0, 1.4] per 1000 anaesthetics.
The majority [n¼66 (51%)] of naloxone administrations occurred during the first 12 h after surgery, and 97 (80%) occurred within the first 24 h (Fig 1) . The median dose of naloxone was 0.2 [inter-quartile range 0.2, 0.4] mg with 31 (24%) receiving naloxone 0.4 mg. The indications for administration were treatment of respiratory depression [n¼72 (56%)] or excessive sedation [n¼56 (44%)], with 11 (8.6%) patients also requiring flumazenil to reverse sedation. Among all the patients who received naloxone, 15 were transferred to ICU, three needed application of a non-invasive positive pressure device to maintain adequate ventilation, and one required cardiopulmonary resuscitation with chest compressions and reintubation.
Naloxone was administered on a standard postoperative ward in 112 patients (87.5%) and in an advance monitored setting (e.g. ICU) in 16 (12.5%) patients. In 104 (83.2%) of the patients, the nursing staff was aware that these patients were heavily sedated, and the staff was frequently assessing them before naloxone administration. In the other 21 (16.8%) patients, the time from the last reassuring nursing check to identification that the patient was over-narcotised was 33 (27, 76) min.
Patients who were administered with naloxone were matched 1:2 with controls based on age, sex, and type of surgery. There were substantial vital-sign differences between patients administered with naloxone and the controls at the postoperative time of naloxone administration (and identical postoperative time for controls). The naloxone patients had lower RASS scores [e2 (e3, e2) vs 0 (0, 0); P<0.001], respiratory rate [8 (6, 12) compared with controls, respectively. Table 1 summarises the patient characteristics. The numbers of patients who were on chronic use of opioids, benzodiazepines, and gabapentinoids were greater compared with the controls (univariable analyses). Table 2 summarises the perioperative and postoperative courses until the time of naloxone administration (or corresponding time for the controls). We observed that those patients who had their chronic gabapentinoid continued into the postoperative period were done so using their home dosing regimen. In univariate analyses, the rates of benzodiazepine and gabapentinoid administration and doses of opioids were found to be greater among patients who received naloxone compared with controls ( Table 2) . Results from the multivariable models assessing clinical and procedural characteristics associated with naloxone administration are presented in Table 3 . From initial multivariable analyses, significant interactions were detected between chronic and postoperative use of gabapentinoids, and similarly with benzodiazepines (Supplementary Table S1 shows the pattern of use of gabapentinoids and benzodiazepinesdchronic, after operation, or bothdbetween naloxone and matched control groups.). Two-way interactions between these medications, and these medications with OSA were assessed, and none were found to be statistically significant (P>0.90, all patients). Continuation of chronic gabapentinoid medications into the postoperative period was observed to be associated with more than six-fold increased risk for naloxone administration [odds ratio (OR) 6.3; 95% CI 2.4, 16.7; P¼0.001]. A post hoc analysis was performed to examine possible associations between naloxone administration and different dosing regimens of chronic gabapentinoid medications, and associations were found with both 'low dose' (OR 5.1; 95% CI 1.4, 18.0; P¼0.013) and 'high dose' (OR 14.1; 95% CI 2.6, 76.4; P¼0.002) chronic regimens.
Episodes of respiratory depression during Phase I recovery were observed in 42 (32.8%) patients who received naloxone and 28 (10.9%) of control patients (P<0.001). Most events were nurse-witnessed episodes of respiratory depression. However, seven cases and two controls were administered with naloxone during Phase I recovery (P¼0.008). A post hoc analysis was performed, which included the occurrence of episodes of respiratory depression as an additional explanatory variable. From this analysis, PACU respiratory events were associated with the need for naloxone administration (OR 5.8; 95% CI 2.8, 12.1; P<0.001), but other associated risk factors remained relatively unchanged.
The postoperative course of the patients who were administered with naloxone was longer and more complicated compared with controls (Table 4) . These patients had longer hospitalisation and higher rates of ICU admissions, emergency response team activations, and postoperative delirium (all P<0.001).
Discussion
The most important observation of this study was that the chronic use of gabapentinoid therapy and its continuation into the postoperative period were associated with overnarcotisation requiring naloxone administration. While these medications are generally considered to have a wide therapeutic index, 5 there is a possibility they can potentiate the respiratory depressant effects of anaesthetic agents and opioids. Specifically, a study of healthy young adult volunteers found that pregabalin potentiated the respiratory depressant effects of remifentanil. 26 Furthermore, we have previously observed that the use of a single preoperative dose of gabapentin or pregabalin before elective joint arthroplasty or laparoscopic surgery was associated with an increased rate of respiratory depression during Phase I anaesthesia recovery. 11, 12 Conceivably, the use of these medications in the perioperative environment where patients are also administered with opioids (and other sedating medications) may have a cumulative effect of increasing the risk for postoperative respiratory depression. Our observation suggests that patients who continue chronic gabapentinoid therapy into the postoperative period warrant high levels of monitoring for signs of respiratory depression. Further, a post hoc analysis further examining this association by dichotomising chronic gabapentinoids into 'low' and 'high' dosing regimens found both regimens associated with increased risk, but this risk was dose dependent. However, these findings should not be used to advocate for abrupt perioperative discontinuation of these medications, because such actions could worsen chronic pain conditions and even elicit an abstinence syndrome. 27 Even though, in the present study, we did not find an association between a single preoperative gabapentinoid dose and postoperative naloxone administration, it should not be interpreted that this practice is devoid of risk. As we indicated in the Methods, the exact type of procedure was one matching criterion. The consequence of this is that, if a patient underwent a procedure using an enhanced recovery protocol that included preoperative gabapentinoid, the two matched controls were also likely to have been administered with a gabapentinoid. This limited our ability to assess this characteristic as a risk factor. Further, this study lacked power to assess for an association between de novo postoperative gabapentinoid use and naloxone administration because of the small number of patients (Supplementary Table S1 ).
In contrast to our study, previous meta-analyses of perioperative gabapentinoids did not detect increase rates of respiratory depression. 2e4 The studies that comprised these meta-analyses did not begin the intervention (gabapentin or pregabalin vs placebo) before hospitalisation; thus, the subjects where we found the highest risk (those using these medications chronically) were a different population. Also, prospective trials are conducted primarily to assess for drug efficacy. Such studies, and the meta-analyses of these trials, have limited capacity to assess risk for uncommon complications because of inadequate power, limited generalisability because of therapeutic regimens designed to enhance safety and exclusion of high-risk patients, and non-uniform reporting of adverse events.
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Another interesting observation was the high risk for naloxone administration associated with continuation of chronic benzodiazepine therapy into the postoperative period. However, when comparing across all benzodiazepine treatment groups simultaneously, the overall model did not reach significance. Nevertheless, this apparent association and the known interactions between benzodiazepines and opioids strongly suggest that these patients warrant heightened vigilance for signs of respiratory depression in the postoperative period.
There were several similarities with our previous study of postoperative naloxone administration (conducted 2008e10). 13 The incidence of naloxone administration was CI, confidence interval; ME, morphine equivalent; NDMR, non-depolarising muscle relaxant; OR, odds ratio. Data are expressed as n (%). * The perioperative period includes the time from the immediate preoperative period through the end of Phase I anaesthetic recovery. The postoperative period includes the time from the end of Phase I recovery to the time of naloxone administration (or corresponding index time for controls). y Data were analysed using conditional logistic regression taking into account the 1:2 matched set study design. For perioperative opioids, the OR presented is for an increase of 10 mg i.v. ME; for the duration of surgery, the OR is for an increase of 60 min; and for postoperative opioids, the OR is for an increase of 1.0 i.v. ME mg h À1 . z All reversals were with neostigmine, as sugammadex was not in clinical practice during the study time frame. ¶ Nine of the cases were paired to a control (in four cases, both controls) also administered with a single preoperative dose of a gabapentinoid.
x Most events were nurse-witnessed episodes of respiratory depression. However, seven cases and two controls were administered with naloxone during Phase I recovery; P¼0.008.
jj Of those receiving postoperative gabapentinoid, 28 (97%) of the naloxone cases and 10 (63%) of the controls had been using gabapentinoids at home before surgery (see Supplementary Table S1 ). # Of those receiving postoperative benzodiazepines, seven (47%) of the naloxone cases and one (9%) of the controls had been using benzodiazepines at home before surgery.
comparable [1.2 (this study) vs 1.6 (previous study) per 1000 general anaesthetics]. The observation that approximately 50% of patients are administered with naloxone within 12 h after discharge from Phase I anaesthesia was similar to our previous study and other reports regarding the timing of episodes of severe opioid-induced respiratory depression. 29 The consistency of these reports supports the supposition that the time period immediately after discharge from Phase I recovery is the highest risk for receiving naloxone. This may not be surprising, as this immediate postoperative period is the time of most intense pain management with opioids. Another similar observation between the present and our previous studies 13 is that episodes of respiratory depression during Phase I recovery are associated with higher rates of naloxone administration after discharge from the PACU. This pattern fits the model proposed by Taenzer and colleagues 30 where 'failure to rescue' events is often preceded by signs of clinical deterioration (in this case, respiratory depression during Phase I recovery). At our institution, patients who experience an episode of respiratory depression have the Phase I period extended by at least 60 min, and if repeated episodes occur, these patients are triaged to a higher level of postoperative monitoring. 22, 23 Nevertheless, even with these additional safety measures, we continue to find higher rates of overnarcotisation in this subset of patients. OSA was similarly found to be a risk factor in both these studies. In the present study, we did not assess for other specific disease states, but rather used the Charlson comorbidity index to assess overall disease burden. With this method, we did not find an association between comorbidity burden and naloxone use. However, assessing for disability using the modified Rankin Scale 18 did find an association between being disabled and risk for naloxone use. The proportion of patients in this cohort who received a naloxone 0.4 mg dose decreased from 48% in our previous study to 24% in the present study; P<0.001. 13 The 0.4 mg dose is the unit dose stored in standard emergency drug kits. While it is difficult to ascertain the decision regarding the exact dose using a retrospective design, the reduction of the full dose may suggest increased familiarity with its dosing among physicians, and suggests that the contemporary practice favours gradual titration of naloxone in incremental doses to reverse opioid respiratory depression without complete reversal of analgesia.
Patients who were administered with naloxone had longer hospital stays and higher rates of emergency response team activations and ICU admissions. Interestingly, these patients also had higher rates of delirium compared with controls. This observation may be multifactorial, 31, 32 reflective in part from opioid-or benzodiazepine-induced cognitive impairments, higher rates of ICU admissions, and higher rates of preoperative disability in the naloxone group. There were no differences in the development of other severe complications. The two in-house mortalities were not related to opioid medications (Table 4) . Similarly, 30-day mortality was similar between the two groups. This study has all inherent limitations of a retrospective study design. Less severe episodes of over-narcotisation may have been treated using more conservative measures or with non-invasive respiratory ventilatory devices; thus, our estimate based on naloxone administration likely includes most severe cases and may be an underestimate of the true incidence of perioperative respiratory depression. Further, the use of this methodology to assess for an association between perioperative gabapentinoid therapy and episodes of overnarcotisation is novel. Although gabapentinoids have been associated with increased risk for sedation, 2e4 naloxone is not a reversal agent for gabapentinoids, but rather reverses one of CI, confidence interval; ME, morphine equivalent; OR, odds ratio. * Data were analysed using conditional logistic regression taking into account the 1:2 matched set study design. y Groups are defined based on chronic home use and postoperative use.
Preoperative use of the given medication is not taken into account when defining groups, but it is included as a separate covariate. the components of postoperative sedationdopioid effects. Thus, our methodology may have missed episodes of severe sedation attributed solely to gabapentinoid use, and therefore, not treated with naloxone.
In conclusion, we found that patients on chronic gabapentinoid therapy when continued after operation are at higher risk for respiratory depression or over-sedation; therefore, they warrant increased postoperative monitoring. In addition, we reconfirmed that episodes of respiratory depression during Phase I anaesthesia recovery are associated with subsequent episodes of opioid-related adverse events after PACU discharge. 
Authors' contributions

